Provided by Tiger Trade Technology Pte. Ltd.

MetaVia Inc

1.51
-0.0400-2.58%
Post-market: 1.540.0300+1.99%16:58 EST
Volume:101.46K
Turnover:158.96K
Market Cap:4.84M
PE:-0.13
High:1.62
Open:1.58
Low:1.50
Close:1.55
52wk High:23.10
52wk Low:1.43
Shares:3.21M
Float Shares:2.29M
Volume Ratio:0.16
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.3639
EPS(LYR):-39.1268
ROE:-168.18%
ROA:-58.41%
PB:0.77
PE(LYR):-0.04

Loading ...

MetaVia Showcases Novel Obesity and Metabolic Therapies at Emerging Growth Conference

Reuters
·
Feb 17

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,

Reuters
·
Feb 14

BUZZ-U.S. STOCKS ON THE MOVE-Opus Genetics, MetaVia, Enbridge

Reuters
·
Feb 13

Metavia Builds Comprehensive Global Patent Protection for Da-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

THOMSON REUTERS
·
Feb 13

MetaVia Inc. Secures Global Patent Protection for DA-1726 Obesity Therapy Through 2041

Reuters
·
Feb 13

BRIEF-Metavia Inc - Announces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel

Reuters
·
Feb 04

Metavia Collaborates with Syntekabio on AI-Driven Drug Discovery

Reuters
·
Feb 04

Metavia Inc. Discloses 2025 Executive Bonus and Compensation Figures

Reuters
·
Jan 28

MetaVia Inc trading halted, volatility trading pause

TIPRANKS
·
Jan 15

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

Reuters
·
Jan 15

Metavia Announces the Pricing of $8.1 Million Underwritten Public Offering

THOMSON REUTERS
·
Jan 15

MetaVia Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 07

Metavia Inc. Unveils Pipeline Advancements Targeting Obesity and MASH

Reuters
·
Jan 06

BRIEF-Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile

Reuters
·
Jan 05

Metavia Inc. Reports Phase 1b Trial Success for DA-1726 in Obesity and Metabolic Disease

Reuters
·
Jan 05

Metavia Inc - 12.3 Mg/Dl Fasted Glucose Reduction by Day 54 in Study

THOMSON REUTERS
·
Jan 05

MetaVia Inc. to Sponsor and Participate in 10th Annual MASH-TAG Conference

Reuters
·
Dec 29, 2025

BRIEF-Metavia Regains Compliance With Nasdaq Minimum Bid Price Requirement

Reuters
·
Dec 22, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:56 AM

Reuters
·
Dec 10, 2025

MetaVia to Implement 1-for-11 Reverse Stock Split

MT Newswires Live
·
Dec 03, 2025